tiprankstipranks
G1 Therapeutics Inc (GTHX)
NASDAQ:GTHX

G1 Therapeutics Stock Price & Analysis

1,688 Followers

GTHX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.84 - $17.49
Previous Close$12.41
Volume998.49K
Average Volume (3M)1.06M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$143.96M
Total Debt (Recent Filing)$28.87M
P/E Ratio-3.1
Beta1.77
Next EarningsNov 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-4.02
Shares Outstanding42,746,806
R-Squared0.13
Standard Deviation0.27
10 Day Avg. Volume1,046,689
30 Day Avg. Volume1,059,900
P/B Ratio8.05
P/S Ratio22.80
P/CF RatioN/A
P/FCF Ratio-4.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside169.53% Upside
Rating ConsensusModerate Buy
Alpha0.00828
Number of Analyst Covering5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

GTHX FAQ

What was G1 Therapeutics’s price range in the past 12 months?
G1 Therapeutics lowest stock price was $3.84 and its highest was $17.49 in the past 12 months.
    What is G1 Therapeutics’s market cap?
    Currently, no data Available
    When is G1 Therapeutics’s upcoming earnings report date?
    G1 Therapeutics’s upcoming earnings report date is Nov 09, 2022 which is in 35 days.
      How were G1 Therapeutics’s earnings last quarter?
      G1 Therapeutics released its earnings results on Aug 03, 2022. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.099.
        Is G1 Therapeutics overvalued?
        According to Wall Street analysts G1 Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does G1 Therapeutics pay dividends?
          G1 Therapeutics does not currently pay dividends.
          What is G1 Therapeutics’s EPS estimate?
          G1 Therapeutics’s EPS estimate is -$0.64.
            How many shares outstanding does G1 Therapeutics have?
            G1 Therapeutics has 42,746,807 shares outstanding.
              What happened to G1 Therapeutics’s price movement after its last earnings report?
              G1 Therapeutics reported an EPS of -$0.92 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 5.181%.
                Which hedge fund is a major shareholder of G1 Therapeutics?
                Among the largest hedge funds holding G1 Therapeutics’s share is Fisher Asset Management LLC. It holds G1 Therapeutics’s shares valued at 11M.

                  ---

                  G1 Therapeutics Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  7
                  The G1 Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  G1 Therapeutics Inc

                  G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis